March 24, 2020 / 10:48 PM / 7 days ago

BRIEF-Fulcrum Therapeutics Announces Complete Data From Phase 1 Trial With Losmapimod In Facioscapulohumeral Muscular Dystrophy (Fshd)

Fulcrum Therapeutics Inc:

* FULCRUM THERAPEUTICS ANNOUNCES COMPLETE DATA FROM PHASE 1 TRIAL WITH LOSMAPIMOD IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)

* FULCRUM THERAPEUTICS INC - LOSMAPIMOD ACHIEVES TARGET ENGAGEMENT IN MUSCLE

* FULCRUM THERAPEUTICS INC - LOSMAPIMOD WAS WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below